Fachthema

Advanced systemic mastocytosis

Rapid responses, few adverse effects seen with targeted agent

Jatros Digital, 28.11.2017
Onkologie | Hämatologie

Daniel J. DeAngelo, MD, of the Dana Farber Cancer Institute, reporting on clinical activity in a phase-I-study of BLU-285 in advanced systemic mastocytosis.

zurück zum ASH Newsroom 2017